135 related articles for article (PubMed ID: 31602686)
41. Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
Nanjyo S; Ohgane K; Yoshioka H; Makishima M; Hashimoto Y; Noguchi-Yachide T
Bioorg Med Chem; 2019 May; 27(10):1952-1961. PubMed ID: 30940565
[TBL] [Abstract][Full Text] [Related]
42. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
[TBL] [Abstract][Full Text] [Related]
43. Zerumbone binding to estrogen receptors: an in-silico investigation.
Eid EEM; Azam F; Hassan M; Taban IM; Halim MA
J Recept Signal Transduct Res; 2018 Aug; 38(4):342-351. PubMed ID: 30396310
[TBL] [Abstract][Full Text] [Related]
44. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A
Front Chem; 2019; 7():602. PubMed ID: 31552220
[TBL] [Abstract][Full Text] [Related]
45. Experimental and computational insights on the recognition mechanism between the estrogen receptor α with bisphenol compounds.
Cao H; Wang F; Liang Y; Wang H; Zhang A; Song M
Arch Toxicol; 2017 Dec; 91(12):3897-3912. PubMed ID: 28616630
[TBL] [Abstract][Full Text] [Related]
46. Binding and stability of indirubin-3-monoxime in the GSK3β enzyme: a molecular dynamics simulation and binding free energy study.
Saravanan K; Hunday G; Kumaradhas P
J Biomol Struct Dyn; 2020 Mar; 38(4):957-974. PubMed ID: 30963817
[TBL] [Abstract][Full Text] [Related]
47. Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens.
Komagata S; Nakajima M; Tsuchiya Y; Katoh M; Kizu R; Kyo S; Yokoi T
J Steroid Biochem Mol Biol; 2006 Jul; 100(1-3):79-86. PubMed ID: 16713253
[TBL] [Abstract][Full Text] [Related]
48. Study of potential inhibition of the estrogen receptor α by cannabinoids using an in silico approach: Agonist vs antagonist mechanism.
Rocha-Roa C; Cortes E; Cuesta SA; Mora JR; Paz JL; Flores-Sumoza M; Márquez EA
Comput Biol Med; 2023 Jan; 152():106403. PubMed ID: 36543006
[TBL] [Abstract][Full Text] [Related]
49. Structure-Based Understanding of Binding Affinity and Mode of Estrogen Receptor α Agonists and Antagonists.
Lee S; Barron MG
PLoS One; 2017; 12(1):e0169607. PubMed ID: 28061508
[TBL] [Abstract][Full Text] [Related]
50. A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).
Callis R; Rabow A; Tonge M; Bradbury R; Challinor M; Roberts K; Jones K; Walker G
J Biomol Screen; 2015 Jul; 20(6):748-59. PubMed ID: 25851036
[TBL] [Abstract][Full Text] [Related]
51. Exploring the Binding Interaction of Raf Kinase Inhibitory Protein With the N-Terminal of C-Raf Through Molecular Docking and Molecular Dynamics Simulation.
Parate S; Rampogu S; Lee G; Hong JC; Lee KW
Front Mol Biosci; 2021; 8():655035. PubMed ID: 34124147
[TBL] [Abstract][Full Text] [Related]
52. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
53. Acylguanidine-BACE1 complex: Insights of intermolecular interactions and dynamics.
Saravanan K; Kumaradhas P
J Theor Biol; 2019 Mar; 464():33-49. PubMed ID: 30571961
[TBL] [Abstract][Full Text] [Related]
54. Investigation of intermolecular interactions and stability of verubecestat in the active site of BACE1: Development of first model from QM/MM-based charge density and MD analysis.
Saravanan K; Sivanandam M; Hunday G; Mathiyalagan L; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2339-2354. PubMed ID: 30044206
[TBL] [Abstract][Full Text] [Related]
55. A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers.
Pavlin M; Spinello A; Pennati M; Zaffaroni N; Gobbi S; Bisi A; Colombo G; Magistrato A
Sci Rep; 2018 Jan; 8(1):649. PubMed ID: 29330437
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the binding performance of flavonoids to estrogen receptor alpha by Autodock, Autodock Vina and Surflex-Dock.
Xue Q; Liu X; Russell P; Li J; Pan W; Fu J; Zhang A
Ecotoxicol Environ Saf; 2022 Mar; 233():113323. PubMed ID: 35183811
[TBL] [Abstract][Full Text] [Related]
57. Computational insights into the interaction mechanisms of estrogen-related receptor alpha with endogenous ligand cholesterol.
Li D; Cai Y; Teng D; Li W; Tang Y; Liu G
Chem Biol Drug Des; 2019 Jul; 94(1):1316-1329. PubMed ID: 30811808
[TBL] [Abstract][Full Text] [Related]
58. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER
Bihani T; Patel HK; Arlt H; Tao N; Jiang H; Brown JL; Purandare DM; Hattersley G; Garner F
Clin Cancer Res; 2017 Aug; 23(16):4793-4804. PubMed ID: 28473534
[No Abstract] [Full Text] [Related]
59. A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations.
Liu HL; Zhong HY; Song TQ; Li JZ
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28832499
[TBL] [Abstract][Full Text] [Related]
60. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
